Tumors that look for their springtime in APRIL

• Published in: Critical reviews in oncology/hematology Vol. 72; no. 2; pp. 91 - 97
• Main Authors: Roosnek, E, Burjanadze, M, Dietrich, P.Y, Matthes, T, Passweg, J, Huard, B
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01-11-2009; Elsevier
• Subjects: Animals; APRIL; Biological and medical sciences; CLL; DLBCL; Hematologic and hematopoietic diseases; Hematology, Oncology and Palliative Medicine; Humans; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunopathology; Inflammation; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Multiple myeloma; Neoplasms - metabolism; TNF; Tumor; Tumor Necrosis Factor Ligand Superfamily Member 13 - physiology; DLBCL; CLL; Multiple myeloma; Tumor; Inflammation; TNF; APRIL; Human; Immunopathology; Prognosis; Targeted therapy; Cytokine; Malignant hemopathy; Malignant tumor; Myeloma; Chronic lymphocytic leukemia; Cancerology; Treatment; Immunoglobulinopathy; Tumor necrosis factor; Lymphoproliferative syndrome; A proliferative inducing ligand; Diffuse large B cell lymphoma; Cancer
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2009.01.006

Abstract Inflammatory cells produce a proliferation inducing ligand (APRIL), one of the most recently cloned members of the tumor necrosis factor (TNF) family. Early experiments implicated APRIL as a promoting factor in the natural course of various cancers, reinforcing the concept that host inflammatory reactions are part of a tumor development. Recent studies have further analyzed the tumor-promoting role of APRIL in patients with solid tumors or with hematological malignancies. Here, we will review the recent literature, and provide evidence that APRIL may be a useful prognostic tool and a potential target in the treatment of some cancers.